Vila Do Conde

Researchers are evaluating the effect and safety of different doses of the medicine NNC0662-0419 in adults living with type 2 diabetes. This phase 2 clinical trial compares NNC0662-0419 with placebo and an approved diabetes medication called semaglutide. The goal is to find out if NNC0662-0419 is effective and safe for lowering blood sugar in people with type 2 diabetes. Participants will receive one of three treatments NNC0662-0419, semaglutide, or placebo. All treatments are given once weekly by injection under the skin. NNC0662-0419 will be given in increasing doses during the study. Semaglutide and placebo will also be given by weekly injections to match the other groups. Treatment assignment is random and participants will not know which treatment they receive. During the study, participants will be monitored regularly for changes in blood sugar levels measured by glycated hemoglobin HbA1c at weeks 16, 28, and 40. Additional assessments include body weight, fasting glucose, cholesterol levels, kidney function, waist size, inflammatory markers, and safety through adverse event tracking. The study lasts about 40 weeks of treatment with follow-up to week 44 to evaluate effects and safety.

Researchers are evaluating how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes T2D, lose weight. The purpose of this clinical study is to find out how safe and effective CagriSema is for body weight loss compared to semaglutide, a medicine already prescribed by doctors. This is a Phase 3 randomized trial lasting about 83 weeks. Participants will be randomly assigned to receive either one of two doses of CagriSema or semaglutide, all given once weekly by injection under the skin during a 72-week treatment period. CagriSema is a new medicine being tested, while semaglutide serves as an active comparator. The study compares these treatments for their effects on weight loss and related health measures. During the study, participants will have regular assessments including body weight, body mass index BMI, waist circumference, cholesterol levels, and blood sugar control measured by HbA1c. Researchers will also monitor physical function and quality of life through questionnaires. Safety is tracked by recording any adverse events up to 80 weeks. The main outcome is the change in body weight from the start of treatment to the end of the 72-week period.